Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 1997
Business Overview: ImmuCell is a biotechnology company focused on developing products to prevent and treat gastrointestinal infections and detect pathogens in water. Key products include FirstDefense and the Kamar Heatmount Detector. The company operates two joint ventures: AgriCell Company, LLC (lactoferrin production) and Clearwater Diagnostics Company, LLC (water diagnostics).
Key Financial Metrics
| Metric | Six Months Ended June 30, 1997 | Six Months Ended June 30, 1996 |
|---|---|---|
| Total Revenues | $2,147,755 | $2,270,120 |
| Net Loss | $(52,466) | $(146,968) |
| Net Loss Per Share | $(0.02) | $(0.06) |
| Cash and Cash Equivalents (Ending) | $931,573 | $1,030,869 |
| Net Cash from Operating Activities | $33,199 | $(274,037) |
| Total Debt (Current + Long Term) | $687,484 | $799,344 |
| Working Capital | $1,242,764 | $1,405,099 |
| Stockholders' Equity | $1,830,591 | $1,877,214 |
Gross Margin: 55% for the six months ended June 30, 1997 (down from 56% in 1996).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 5% ($122,365) compared to the prior year six-month period. This was driven by a significant drop in grant income (down $144,080) and collaborative R&D revenue (down $10,000), partially offset by a slight increase in product sales (up $11,715).
- Improved Profitability: Net loss improved significantly, decreasing by $94,502 (64%) year-over-year. This improvement was primarily due to a $295,883 (36%) reduction in Research and Development (R&D) expenses.
- Expense Management: General and administrative expenses decreased by $30,306 (9%). However, sales and marketing expenses increased by $85,090 (23%) to support product growth.
- Liquidity: Cash and cash equivalents decreased by $112,868. Total debt obligations were reduced by $111,860 through principal payments.
Outlook, Risks, and Management Commentary
- Strategy: Management continues to invest in R&D to demonstrate efficacy in Phase I/II clinical trials, with the strategy of pursuing corporate partners to fund continued development in exchange for marketing rights.
- Future Losses: The company expects to incur operating losses in the future as it aggressively develops new products.
- Liquidity Position: Management believes it has sufficient capital resources to meet working capital requirements and finance operations for the next twelve months.
- Grant Funding: A $100,000 Phase I Small Business Innovation Research grant obtained in September 1996 is being utilized for water test development. Approximately $22,000 remained available as of July 1, 1997.
- Joint Ventures: AgriCell is completing a commercial production facility for lactoferrin. Clearwater Diagnostics entered a distribution agreement for its Crypto-Scan test in the United Kingdom.
- Risks: The company relies heavily on product sales of FirstDefense and Kamar Heatmount (93% of product sales). Continued R&D spending is necessary for growth but contributes to net losses.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of product sales given that two products (FirstDefense and Kamar Heatmount) account for over 90% of product revenue.
- Grant Dependency: Assess the impact of the significant decline in grant income ($170,961 in 1996 vs. $26,881 in 1997) on future cash flow projections.
- Debt Maturity: Review the debt schedule; approximately $117,000 in principal payments are due in the remainder of 1997, with significant obligations in 1998 ($230,000).
- R&D Efficiency: Monitor the correlation between reduced R&D spend and the timeline for Phase I/II clinical trial results and potential corporate partnerships.
- Cash Burn: Confirm the company's ability to maintain positive operating cash flow without further dilution or debt financing, given the $113,000 cash decrease in the first half of the year.